Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Account Payables (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Change in Account Payables for 14 consecutive years, with -$63000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 62.5% year-over-year to -$63000.0, compared with a TTM value of -$1.2 million through Dec 2025, up 79.05%, and an annual FY2025 reading of -$1.3 million, down 216.67% over the prior year.
  • Change in Account Payables was -$63000.0 for Q4 2025 at Enanta Pharmaceuticals, up from -$723000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.6 million in Q1 2023 and bottomed at -$5.1 million in Q2 2022.
  • Average Change in Account Payables over 5 years is -$218700.0, with a median of -$623000.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables soared 1796.21% in 2021, then tumbled 2923.33% in 2022.
  • Year by year, Change in Account Payables stood at -$1.7 million in 2021, then surged by 58.75% to -$686000.0 in 2022, then soared by 854.23% to $5.2 million in 2023, then plummeted by 103.25% to -$168000.0 in 2024, then soared by 62.5% to -$63000.0 in 2025.
  • Business Quant data shows Change in Account Payables for ENTA at -$63000.0 in Q4 2025, -$723000.0 in Q3 2025, and -$1.3 million in Q2 2025.